The anti-inflammatory potency of glucocorticoids derives from their capacity to simultaneously suppress multiple convergent arms of the inflammatory cascade at the transcriptional level. Rather than blocking a single mediator or receptor, activated GR (glucocorticoid receptor) monomers physically inhibit the transcription factors that drive the entire program of inflammatory gene expression, while also inducing proteins that suppress inflammation at the post-translational level. This broad suppression of the inflammatory transcriptome is both the therapeutic advantage and the source of the immunosuppressive complications of glucocorticoid use.
The upstream suppression of eicosanoid synthesis by glucocorticoids depends on two convergent mechanisms targeting arachidonic acid availability. The first and most pharmacologically important is the induction of annexin-A1 (lipocortin-1), an endogenous phospholipase inhibitor whose expression is upregulated by GR (glucocorticoid receptor)-mediated transactivation. Annexin-A1 binds to and inhibits cytosolic PLA2 (phospholipase A2), the enzyme that releases arachidonic acid from membrane phospholipids, thereby reducing substrate availability for both the cyclooxygenase and lipoxygenase pathways simultaneously. This single action suppresses prostaglandin, thromboxane, and leukotriene synthesis in parallel, which accounts for the broader anti-inflammatory spectrum of glucocorticoids compared with non-steroidal anti-inflammatory drugs (NSAIDs), which block only cyclooxygenase. The second mechanism is the transcriptional repression of COX-2 (cyclooxygenase-2) gene expression through NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells) and AP-1 (activator protein 1) inhibition, preventing the inducible upregulation of COX-2 that would otherwise amplify prostaglandin output at sites of inflammation.1
The NF-kappaB pathway is the master regulator of the acute inflammatory transcriptome, and its inhibition by glucocorticoids operates through three distinct mechanisms that act in parallel. First, GR-alpha monomers directly tether to the p65 subunit of NF-kappaB, preventing p65 from interacting with its coactivator complexes and blocking transcription of NF-kappaB target genes. Second, glucocorticoids induce transcription of IkappaB-alpha (the inhibitory protein that sequesters NF-kappaB in the cytoplasm in its inactive form) through a GRE (glucocorticoid response element)-dependent mechanism, increasing the cytoplasmic pool of IkappaB-alpha and reducing the nuclear NF-kappaB available for gene activation. Third, GR-alpha recruits histone deacetylase 2 (HDAC2) to the promoters of NF-kappaB-activated inflammatory genes, reversing the histone acetylation that maintains those genes in an open, transcriptionally active chromatin configuration.2 The HDAC2 mechanism is particularly relevant to glucocorticoid resistance in COPD (chronic obstructive pulmonary disease) and in smokers: oxidative stress from cigarette smoke causes oxidative modification and inactivation of HDAC2 in airway macrophages, impairing GR-alpha recruitment of HDAC2 to inflammatory gene promoters and reducing corticosteroid responsiveness at the cellular level.
The cytokine network suppressed by glucocorticoids spans both the initiating signals and the amplification circuits of inflammation. At the level of initiation, glucocorticoids suppress IL (interleukin)-1beta and TNF-alpha (tumor necrosis factor-alpha), the principal proximal cytokines released by activated macrophages and dendritic cells. These two cytokines are primarily responsible for the systemic manifestations of inflammation including fever (via prostaglandin E2 in the hypothalamus), acute-phase protein induction in the liver, and the recruitment of additional immune cells to sites of inflammation. At the amplification level, glucocorticoids suppress IL-2 (interleukin-2) production by T lymphocytes, which is the principal growth and survival signal for T cell clonal expansion, and IL-6 (interleukin-6), which drives the hepatic acute-phase response and has broad effects on immune cell differentiation. IFN-gamma (interferon-gamma), produced by activated T helper type 1 (Th1) cells and NK (natural killer) cells, is suppressed, reducing macrophage activation and major histocompatibility complex class II upregulation. IL-8 (interleukin-8) production, which drives neutrophil chemotaxis to sites of inflammation, is also reduced, contributing to the redistribution of neutrophils described in the following section.1
The suppression of iNOS (inducible nitric oxide synthase) gene expression is a clinically significant anti-inflammatory action of glucocorticoids mediated through NF-kappaB inhibition. Inducible nitric oxide synthase, unlike the constitutively expressed endothelial and neuronal NOS isoforms, is induced in macrophages, vascular smooth muscle, and other cells by pro-inflammatory cytokines including IL-1beta and TNF-alpha. The high-output nitric oxide (NO) produced by iNOS at sites of inflammation contributes to vasodilation, increased vascular permeability, and oxidative tissue damage through peroxynitrite formation. Glucocorticoid suppression of iNOS reduces vascular permeability and tissue edema, contributing to the rapid reduction in local swelling that is among the first clinically visible effects of glucocorticoid administration.3 The adhesion molecules ICAM-1 (intercellular adhesion molecule-1) and E-selectin, whose expression is driven by NF-kappaB and is essential for leukocyte rolling, adhesion, and transmigration across the vascular endothelium, are also suppressed, reducing the influx of new inflammatory cells to sites of ongoing inflammation.
Glucocorticoids induce MKP-1 (mitogen-activated protein kinase phosphatase-1), an endogenous phosphatase that dephosphorylates and inactivates the p38 MAPK (mitogen-activated protein kinase) and JNK (c-Jun N-terminal kinase) pathways. These kinase pathways stabilize the messenger RNA (mRNA) of numerous pro-inflammatory cytokines including TNF-alpha and IL-6 by phosphorylating AU-rich element binding proteins that would otherwise target cytokine mRNA for rapid degradation. MKP-1 induction by glucocorticoids accelerates cytokine mRNA decay, reducing cytokine protein output at the post-transcriptional level independently of transcriptional repression. This dual action — transcriptional repression through NF-kappaB and AP-1 inhibition plus post-transcriptional destabilization through MKP-1 — explains why glucocorticoids reduce cytokine output more completely than agents that target only one of these mechanisms.
Upstream (lipid mediators): Annexin-A1 induction → PLA2 inhibition → reduced arachidonic acid availability for all eicosanoid pathways. Transcriptional repression of COX-2 and 5-LOX (5-lipoxygenase).
Transcriptional (cytokines): NF-kappaB tethering + IkappaB-alpha induction + HDAC2 recruitment suppress IL-1beta, IL-2, IL-6, IL-8, TNF-alpha, IFN-gamma, GM-CSF (granulocyte-macrophage colony-stimulating factor). AP-1 inhibition suppresses matrix metalloproteinases and additional growth factors.
Vascular/endothelial: iNOS suppression reduces NO-mediated vasodilation and edema. ICAM-1 and E-selectin suppression reduces leukocyte transmigration.
Post-transcriptional: MKP-1 induction destabilizes cytokine mRNA, reducing protein output independently of transcriptional effects.
Glucocorticoids produce characteristic, predictable changes in circulating leukocyte populations within hours of administration. These changes reflect distinct mechanisms in different cell types and have direct clinical relevance: they inform interpretation of the white blood cell count in steroid-treated patients, are exploited diagnostically, and represent the cellular basis of both the therapeutic immunosuppression and the infectious complications of glucocorticoid therapy.
The most clinically familiar leukocyte change produced by glucocorticoids is a neutrophilia, which typically appears within 4 to 6 hours of administration and can raise the absolute neutrophil count by 2- to 3-fold in the absence of any infectious stimulus. This neutrophilia does not reflect increased bone marrow production or enhanced neutrophil function; rather, it results from two concurrent redistribution phenomena. First, glucocorticoids suppress the expression of the adhesion molecules L-selectin and the beta-2 integrin Mac-1 on the neutrophil surface, reducing the margination of neutrophils to the vascular endothelium that normally accounts for approximately 50% of the circulating neutrophil pool. Second, glucocorticoids accelerate the release of mature neutrophils from bone marrow storage pools. The result is a transient expansion of the circulating pool without any enhancement of antimicrobial function. The clinical significance is important: an elevated neutrophil count in a patient on glucocorticoids does not indicate bacterial infection in the same way it would in a non-treated patient, and cannot be used as a reliable inflammatory marker in this context.4
Lymphopenia, particularly affecting T lymphocytes, is the predominant mechanism of therapeutic immunosuppression by glucocorticoids and is produced through redistribution rather than cytolysis in most human clinical contexts. Within hours of glucocorticoid administration, circulating T lymphocytes, B lymphocytes, and NK (natural killer) cells decrease markedly (typically by 70 to 90% for T cells at pharmacological doses) due to GR (glucocorticoid receptor)-mediated alterations in homing receptor expression and cytokine signals that redirect lymphocytes from blood to lymphoid tissues including spleen, lymph nodes, and bone marrow. This redistribution is reversible within 24 hours of a single dose. The suppression of IL-2 (interleukin-2) production by T helper cells is the principal mechanism by which glucocorticoids inhibit T cell clonal expansion during an ongoing immune response: without IL-2, antigen-activated T cells cannot proliferate to mount an effective adaptive immune response.5 At high pharmacological concentrations or with prolonged exposure, glucocorticoids also induce apoptosis in immature thymocytes and in activated T cells through GR-dependent transcriptional activation of pro-apoptotic genes, though this mechanism is less prominent in mature peripheral T cells in humans than in rodent models.
Macrophages and DC (dendritic cells) are profoundly affected by glucocorticoids at multiple functional levels. In macrophages, glucocorticoids suppress the classical activation (M1) phenotype driven by IFN-gamma (interferon-gamma) and lipopolysaccharide (LPS): they reduce the respiratory burst, impair phagocytic activity, suppress antigen presentation by reducing major histocompatibility complex (MHC) class II expression on the cell surface, and reduce the production of the pro-inflammatory cytokines IL-1beta, TNF-alpha (tumor necrosis factor-alpha), and IL-12 (interleukin-12). The capacity of macrophages to kill intracellular pathogens is consequently reduced, contributing to the risk of opportunistic infections with organisms normally controlled by cell-mediated immunity. In dendritic cells, glucocorticoids impair maturation and migration to lymph nodes, reduce the upregulation of costimulatory molecules CD80 (B7-1) and CD86 (B7-2), and shift the cytokine profile from Th1 (T helper cell type 1)-promoting (high IL-12) to Th2 (T helper cell type 2)-promoting or tolerogenic patterns, reducing the efficiency of priming naive T cells toward effector responses.2
Eosinophil and mast cell suppression accounts for the prominent efficacy of glucocorticoids in allergic diseases including asthma and allergic rhinitis, where these cells are the predominant effectors of type 2 inflammation. Glucocorticoids promote eosinophil apoptosis through GR-dependent mechanisms, reducing tissue eosinophil numbers rapidly and profoundly; the fall in blood eosinophil count following a single dose of systemic glucocorticoid is one of the most sensitive and fastest indicators of glucocorticoid bioactivity and has historically been used to demonstrate GR engagement in pharmacodynamic studies. Mast cell numbers in tissues are reduced with prolonged glucocorticoid use, and their activation is impaired through suppression of SCF (stem cell factor) production, which is the principal survival and differentiation signal for mast cells in tissues. The reduction in mast cell mediator release (histamine, cysteinyl leukotrienes, prostaglandin D2) contributes to the reduction in bronchospasm, mucus production, and vascular permeability in allergic airways disease.6
The complete blood count (CBC) in a patient on systemic glucocorticoids requires reinterpretation of normal reference ranges. The expected pattern includes: neutrophilia (2–3-fold rise) from demargination and marrow release, not infection; lymphopenia (T cells predominantly) from redistribution to lymphoid tissues; monocytopenia from redistribution; eosinopenia, which in the glucocorticoid-treated patient actually indicates active GR engagement and adequate drug effect, not absence of allergic disease. A rising eosinophil count in a patient who should be therapeutically suppressed warrants consideration of non-compliance or inadequate dosing. Conversely, a left-shifted neutrophilia with toxic granulations on peripheral smear suggests superimposed infection despite the background steroid-induced neutrophilia.
An important immune cell effect with direct pharmacological consequence is the disruption of the RANKL (receptor activator of nuclear factor kappa-B ligand)/OPG (osteoprotegerin) balance. Glucocorticoids increase the expression of RANKL by osteoblasts and stromal cells while simultaneously reducing OPG expression. Because RANKL drives osteoclast differentiation and activation while OPG neutralizes it as a decoy receptor, this shift promotes net bone resorption. Simultaneously, glucocorticoids suppress osteoblast differentiation and promote osteoblast apoptosis through GR-mediated transcriptional effects, reducing bone formation. The net result is an imbalance between increased resorption and decreased formation that produces glucocorticoid-induced osteoporosis (GIO), addressed in detail in Module 3.
Glucocorticoids occupy a contested but clearly defined role in critical illness pharmacology. The evidence base has shifted substantially over the past two decades, with large randomized trials clarifying which severely ill populations benefit from glucocorticoids and which do not. In organ transplantation, glucocorticoids remain integral to both induction and maintenance immunosuppression, though the trend toward steroid-minimization and steroid-avoidance protocols reflects both their adverse effect burden and the efficacy of newer targeted immunosuppressants.
The use of glucocorticoids in septic shock has been shaped by a series of conflicting large trials that together define a narrow, evidence-based indication. The initial rationale was that sepsis produces a relative adrenal insufficiency (AI) in some patients through suppression of HPA (hypothalamic-pituitary-adrenal) axis responsiveness by inflammatory mediators, impaired cortisol synthesis due to adrenal ischemia or adrenal gland involvement, and increased cortisol clearance, leaving a subset of patients with inadequate cortisol reserve for the degree of physiological stress imposed by severe sepsis. The CORTICUS (Corticosteroid Therapy of Septic Shock) trial (2008) found no mortality benefit from hydrocortisone 50 mg IV (intravenous) every 6 hours in a broad population of septic shock patients, and specifically found that the response to a short ACTH (adrenocorticotropic hormone) stimulation test did not identify a subgroup who benefited. The ADRENAL (Adjunctive Corticosteroid Treatment in Patients with Septic Shock) trial (2018) compared continuous hydrocortisone infusion at 200 mg per day versus placebo in mechanically ventilated septic shock patients and found no difference in 90-day mortality, though the glucocorticoid group achieved faster shock reversal, faster liberation from mechanical ventilation, and faster ICU (intensive care unit) discharge.13
The APROCCHSS (Activated Protein C and Corticosteroids for Human Septic Shock) trial (2018), by contrast, found a significant mortality benefit with the combination of hydrocortisone plus fludrocortisone in patients with more severe septic shock requiring higher vasopressor doses. The current clinical synthesis from these trials and subsequent guidelines is that low-dose hydrocortisone (200 mg per day by continuous infusion or divided doses) is appropriate for patients with septic shock refractory to adequate fluid resuscitation and vasopressor therapy at doses equivalent to norepinephrine greater than 0.25 micrograms per kilogram per minute, and should not be used in patients who respond to initial resuscitation.7
The most definitively evidence-supported use of glucocorticoids in acute respiratory failure is in ARDS (acute respiratory distress syndrome) associated with COVID-19 (coronavirus disease 2019). The RECOVERY (Randomized Evaluation of COVID-19 Therapy) trial, a large adaptive platform trial conducted in the United Kingdom during the COVID-19 pandemic, demonstrated that dexamethasone 6 mg once daily for up to 10 days reduced 28-day mortality in hospitalized COVID-19 patients requiring respiratory support: the benefit was concentrated in patients requiring supplemental oxygen or mechanical ventilation, with a number needed to treat of approximately 8 for mechanically ventilated patients and approximately 25 for those requiring supplemental oxygen alone. Patients not requiring oxygen showed no benefit and a non-significant trend toward harm, underscoring the principle that the anti-inflammatory benefit of glucocorticoids in infectious respiratory failure is relevant only when dysregulated host inflammation, rather than active viral replication, is the dominant driver of organ injury.8 Dexamethasone was chosen for the RECOVERY trial on pharmacokinetic grounds: its long biologic duration of action (36 to 54 hours) permits once-daily dosing, its absence of mineralocorticoid activity avoids sodium and fluid retention in severely ill patients already at risk of volume overload, and its high potency achieves adequate immunosuppression at a small tablet dose suitable for resource-limited settings.
Glucocorticoids remain the standard of care for the management of cerebral edema caused by primary or metastatic brain tumors. Dexamethasone is the preferred agent because of its high potency, absence of mineralocorticoid activity, and long duration of action, and it is administered at doses of 4 to 16 mg per day in divided doses depending on severity. The mechanism of benefit in peritumoral edema involves both suppression of the inflammatory component of edema and the downregulation of VEGF (vascular endothelial growth factor) expression by tumor cells and surrounding reactive astrocytes, reducing the vascular hyperpermeability that drives vasogenic edema. In bacterial meningitis, dexamethasone 0.15 mg per kilogram every 6 hours for 4 days, initiated with or immediately before the first antibiotic dose, reduces the risk of severe neurological sequelae (sensorineural hearing loss, particularly in Haemophilus influenzae type b meningitis) through suppression of the intense inflammatory response triggered in the subarachnoid space by bacterial lysis from antibiotic treatment.3
In organ transplantation, glucocorticoids have historically been essential components of both induction immunosuppression (high-dose methylprednisolone at the time of transplant surgery) and maintenance immunosuppression (chronic low-dose prednisone typically 5 mg per day in kidney transplant recipients). Their mechanism in this context is primarily through the broad suppression of T cell activation described in Section 2: suppression of IL-2 (interleukin-2), MHC (major histocompatibility complex) class II downregulation on antigen-presenting cells, and reduction in the costimulatory signals required for alloreactive T cell clonal expansion. Glucocorticoids are synergistic with CNI (calcineurin inhibitor) drugs (cyclosporine and tacrolimus), which block the calcineurin-NFAT (nuclear factor of activated T cells) pathway of IL-2 gene transcription; the combination suppresses IL-2 production at both the transcriptional (CNI) and the post-transcriptional and upstream cytokine-signaling (glucocorticoid) levels. An important pharmacokinetic interaction requires monitoring: CYP3A4 (cytochrome P450 3A4) inhibition by cyclosporine can moderately increase methylprednisolone exposure, and CYP3A4 induction by rifampin or anticonvulsants can precipitate acute rejection by reducing glucocorticoid levels below the therapeutic threshold.9 Steroid-minimization protocols, in which prednisone is tapered to discontinuation within 3 to 12 months post-transplant, are now standard in many kidney transplant centers for low-immunological-risk recipients, reducing the long-term burden of glucocorticoid adverse effects without substantially increasing rejection risk in appropriately selected patients.
Hydrocortisone in septic shock should be considered when: (1) adequate fluid resuscitation has been given, (2) vasopressor requirement is high (norepinephrine equivalent greater than 0.25 micrograms per kilogram per minute) and escalating, (3) the clinical course is consistent with refractory septic shock rather than cardiogenic or obstructive shock. Dose: hydrocortisone 200 mg per day by continuous IV infusion (preferred to reduce cortisol concentration fluctuations) or 50 mg IV every 6 hours. Duration: until vasopressor discontinuation or 7 days, whichever comes first. Fludrocortisone 50 micrograms per day orally may be added as per the APROCCHSS protocol. Do not use dexamethasone in this setting: its lack of mineralocorticoid activity is relevant here, and its long duration makes titration and discontinuation difficult.
Glucocorticoids have disease-specific roles that differ markedly in dose, duration, and intent across rheumatology, pulmonary medicine, and dermatology. In rheumatology, they are principally used as bridge therapy while awaiting the onset of disease-modifying agents, and as suppressive therapy during flares. In pulmonary medicine, the inhaled route delivers high local concentrations with minimal systemic effect. In dermatology, topical preparations exploit the same pharmacokinetic principle, with potency classified by a standardized vasoconstrictor assay.
In RA (rheumatoid arthritis), glucocorticoids serve two principal roles. As bridge therapy, low-dose prednisone (typically 5 to 10 mg per day) is used at the time of diagnosis or disease modification strategy change to control synovial inflammation while awaiting the 8 to 12-week onset of effect of methotrexate or other conventional synthetic disease-modifying antirheumatic drugs. The COBRA (Combinatietherapie Bij Reumatoide Artritis) trial established that an initial step-down high-dose protocol (prednisone 60 mg daily tapered over weeks) combined with methotrexate and sulfasalazine produced superior early radiographic protection compared with sulfasalazine alone, providing evidence for the disease-modifying potential of early intensive glucocorticoid therapy in RA.10 As flare management, short courses of prednisone (20 to 40 mg for 5 to 10 days) rapidly suppress the synovial inflammation, elevated ESR (erythrocyte sedimentation rate), and elevated CRP (C-reactive protein) of acute RA flares, bridging patients to adjusted disease-modifying therapy. Intra-articular injections of triamcinolone acetonide or methylprednisolone acetate are highly effective for monoarticular or oligoarticular flares and are preferred over systemic therapy when only one or two joints are actively inflamed, as they concentrate the drug at the target site while minimizing systemic exposure.
In SLE (systemic lupus erythematosus), glucocorticoid dosing spans an enormous range depending on the severity and organ involvement of the flare. Mild mucocutaneous or musculoskeletal flares may be managed with hydroxychloroquine dose optimization and prednisone 20 to 30 mg per day for a short course. Severe lupus nephritis, neuropsychiatric lupus, lupus pneumonitis, or lupus myocarditis requires high-dose IV methylprednisolone pulse therapy (500 to 1000 mg per day for 3 consecutive days), followed by high-dose oral prednisone (1 mg per kilogram per day) with gradual tapering over months guided by disease activity markers and renal function, combined with mycophenolate mofetil (MMF) or cyclophosphamide for organ-preserving immunosuppression. The glucocorticoid works through the immune cell mechanisms described in Section 2 to rapidly suppress autoantibody-mediated tissue injury, complement activation, and immune complex deposition, while the longer-acting immunosuppressants provide sustained disease control that allows the steroid to be tapered.5
PMR (polymyalgia rheumatica) and GCA (giant cell arteritis) require high-dose prolonged glucocorticoid therapy because the underlying vasculitic process is both glucocorticoid-responsive and highly susceptible to relapse during premature dose reduction. PMR is treated with prednisone 15 to 25 mg per day, with the dose maintained until symptoms resolve and inflammatory markers normalize, then slowly tapered over 12 to 24 months or longer, as relapse rates are high with rapid tapering. GCA, the related large-vessel vasculitis affecting cranial arteries (temporal artery predominantly) in patients over age 50, requires prednisone 40 to 60 mg per day as initial therapy to prevent irreversible ischemic complications including vision loss from anterior ischemic optic neuropathy; in cases with visual symptoms or amaurosis fugax, IV methylprednisolone pulse therapy is initiated immediately before oral prednisone, as even 24 hours of delay in treatment can result in permanent blindness. The biological agent tocilizumab (IL-6 receptor antagonist) has been approved as adjunctive therapy in GCA and allows a more rapid prednisone taper with lower relapse rates compared with prednisone monotherapy, representing one of the first effective steroid-sparing strategies in this disease.11
ICS (inhaled corticosteroids) pharmacology is defined by the pharmacokinetic dissociation between high local drug concentration in the airways and low systemic bioavailability, achieved through two complementary mechanisms: poor gastrointestinal absorption of swallowed drug, and extensive first-pass hepatic metabolism of the fraction that is absorbed systemically. Budesonide, fluticasone propionate, ciclesonide, and beclomethasone dipropionate differ substantially in their degree of first-pass metabolism and in their systemic bioavailability from the inhaled fraction that bypasses the lung and reaches the systemic circulation directly through the airway vasculature. Fluticasone propionate has the highest topical anti-inflammatory potency and the lowest systemic bioavailability (approximately 1% from the gastrointestinal component and approximately 20 to 30% of the inhaled fraction reaching the systemic circulation) among commonly used ICS agents. Budesonide undergoes approximately 85 to 90% first-pass hepatic metabolism of both the swallowed and absorbed fractions. Ciclesonide is an inactive prodrug activated by esterases in the airway epithelium, further enhancing its topical selectivity. In step therapy for asthma, ICS at low and medium doses have a favorable safety profile in adults, but high-dose ICS (fluticasone propionate greater than 500 micrograms per day or equivalent) is associated with measurable HPA (hypothalamic-pituitary-adrenal) axis suppression, posterior subcapsular cataracts, and skin thinning, and should be used at the lowest effective dose with regular review.6
Topical glucocorticoids are classified into seven potency classes (Class I, superpotent, through Class VII, lowest potency) based on the McKenzie-Stoughton vasoconstrictor assay, which measures skin blanching as a surrogate for glucocorticoid receptor engagement in the dermis. Class I agents (clobetasol propionate 0.05%, halobetasol propionate) should be used for no more than 2 consecutive weeks on limited body surface area and avoided on the face, axillae, groin, and intertriginous areas. Class VI–VII agents (hydrocortisone 1%, desonide) are safe for facial and intertriginous use and in children. Vehicle selection is as pharmacologically important as potency class: ointments have the highest skin penetration (occlusive effect enhances absorption), creams are intermediate and better tolerated on moist or intertriginous skin, and lotions are preferred for scalp application. Skin atrophy, striae, and telangiectasia result from GR-dependent suppression of collagen synthesis in dermal fibroblasts and represent irreversible structural changes with prolonged high-potency topical use.
The perioperative period presents a specific and high-stakes context for glucocorticoid management: surgical stress normally drives a large cortisol surge that is essential for maintaining hemodynamic stability during and after major operations, and patients with HPA (hypothalamic-pituitary-adrenal) axis suppression from exogenous glucocorticoids cannot mount this response independently. The consequences of an unrecognized adrenal crisis in the postoperative period can be catastrophic and are entirely preventable with appropriate prophylaxis.
The normal cortisol response to surgery is proportional to the magnitude and duration of the operative stress. Minor procedures under local anesthesia produce little or no cortisol elevation. Regional anesthesia attenuates but does not abolish the cortisol response compared with general anesthesia. Major abdominal or thoracic surgery under general anesthesia produces a cortisol response beginning at skin incision, peaking during the most stressful portions of the operation (bowel manipulation, aortic cross-clamp, extensive dissection), with plasma cortisol values reaching 40 to 80 micrograms per deciliter and remaining elevated for 24 to 72 hours postoperatively depending on surgical complexity and postoperative complications. This cortisol surge serves to mobilize glucose for tissue repair, maintain vascular tone through sensitization to catecholamines, and modulate the early postoperative inflammatory response. Patients on pharmacological glucocorticoid therapy whose HPA axis is suppressed cannot generate this response independently and are at risk for AI (adrenal insufficiency) manifesting as unexplained hypotension, failure to mount appropriate tachycardia, hypothermia, hyponatremia, and confusion in the postoperative period.12
Risk stratification for perioperative adrenal insufficiency follows the same dose-duration framework established in Module 1. Patients taking prednisone equivalent less than 5 mg per day or any glucocorticoid for less than 3 weeks have minimal HPA suppression and require no supplementation beyond their usual dose; they should simply continue their chronic regimen through the perioperative period. Patients taking prednisone 5 to 20 mg per day for 3 or more weeks have partial suppression and uncertain stress response capacity; these patients receive supplementation proportional to surgical stress. Patients taking prednisone greater than 20 mg per day for more than 3 weeks, or any patient with Cushingoid features regardless of stated dose, are presumed to have substantial HPA suppression and receive full stress-dose supplementation for major procedures. Patients who have been off glucocorticoids for more than 3 months at the time of surgery generally have recovered HPA function and require no special management unless they developed adrenal atrophy that was documented during their treatment course.12
Stress-dose supplementation protocols are stratified by procedural category. For minor procedures (dental extractions, endoscopy, minor outpatient surgery), no supplementation beyond the usual morning dose is required; the patient takes their normal oral (PO) dose and no additional coverage is needed. For moderate procedures (inguinal hernia repair, cholecystectomy, joint replacement, major endoscopic procedures under general anesthesia), hydrocortisone 50 mg IV (intravenous) at the time of anesthetic induction is followed by 25 mg IV every 8 hours for 24 hours, then return to the usual chronic dose. For major procedures (cardiac surgery, major abdominal surgery, major vascular surgery, transplant surgery), hydrocortisone 100 mg IV at induction is followed by 50 mg IV every 8 hours for the first 24 hours, with gradual taper over 48 to 72 hours back to the pre-operative chronic dose, adjusted for postoperative complications that may prolong the stress state.12 In patients who cannot take oral medication postoperatively, intramuscular (IM) hydrocortisone 100 mg provides reliable absorption and is the preferred emergency route when IV access is unavailable.
Perioperative adrenal crisis must be distinguished from other causes of postoperative hypotension, as its treatment (glucocorticoid administration) is specific and urgent. Clinical clues that suggest adrenal crisis rather than hypovolemia or cardiac dysfunction include: hypotension refractory to fluid resuscitation and vasopressors, disproportionate hemodynamic instability relative to estimated blood loss, hyponatremia without hyperkalemia (secondary AI does not cause mineralocorticoid deficiency), and a history of chronic glucocorticoid use that was not disclosed preoperatively. In any hemodynamically unstable postoperative patient on or recently discontinuing glucocorticoids, empiric hydrocortisone 100 mg IV should be given without awaiting cortisol testing. A random cortisol drawn before the dose allows retrospective diagnosis. Response to hydrocortisone is typically rapid — hemodynamic improvement within 30 to 60 minutes supports the diagnosis.
Patients requiring glucocorticoids for chronic autoimmune or inflammatory diseases who are scheduled for elective surgery present an additional management consideration: whether to continue, reduce, or temporarily modify their immunosuppressive regimen to optimize wound healing and reduce infectious risk. In general, the underlying disease that necessitates glucocorticoid therapy carries greater risk of perioperative complications if inadequately controlled than does moderate-dose glucocorticoid continuation. For most patients on prednisone 10 to 20 mg per day for rheumatologic or inflammatory bowel disease indications, continuation through the perioperative period with stress-dose supplementation as above is preferred over pre-operative tapering. However, in patients on very high doses (prednisone greater than 40 mg per day), elective surgery should be deferred if possible to allow dose reduction, as doses in this range are associated with impaired wound healing, increased surgical site infection rates, and anastomotic dehiscence. In patients on biologic immunosuppressants in addition to glucocorticoids, withholding the biologic for one to two half-lives before surgery is often recommended by subspecialty guidelines, but this decision must be individualized in consultation with the prescribing rheumatologist or gastroenterologist.12
Minor surgery (local/regional, no general anesthesia, discharge same day): Continue usual oral dose on day of surgery. No supplementation required. If patient is NPO (nothing by mouth), give usual dose IV as hydrocortisone equivalent.
Moderate surgery (general anesthesia, 1–2 day hospitalization): Hydrocortisone 50 mg IV at induction, then 25 mg IV every 8 hours for 24 hours. Resume usual oral dose when tolerating diet. If usual dose is greater than 25 mg hydrocortisone equivalent, resume the higher dose.
Major surgery (prolonged general anesthesia, ICU care anticipated): Hydrocortisone 100 mg IV at induction, then 50 mg IV every 8 hours for 24–48 hours, tapering to usual dose over 48–72 hours as clinical course permits. Extend supplementation if fever, hypotension, or active infection prolongs the stress state.
Emergency surgery in unknown HPA status: Give hydrocortisone 100 mg IV empirically. Do not delay surgery for cortisol testing. Obtain random cortisol + ACTH sample before the dose if timing allows.
Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids — new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711–1723.
doi:10.1056/NEJMra050541Barnes PJ. Glucocorticosteroids: current and future directions. Br J Pharmacol. 2011;163(1):29–43.
doi:10.1111/j.1476-5381.2010.01199.xChrousos GP. Adrenocorticosteroids and adrenocortical antagonists. In: Katzung BG, ed. Basic and Clinical Pharmacology. 14th ed. New York, NY: McGraw-Hill; 2018:687–710.
Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30.
doi:10.1186/1710-1492-9-30Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol. 2008;4(10):525–533.
doi:10.1038/ncprheum0898Barnes PJ. Inhaled corticosteroids. Pharmaceuticals (Basel). 2010;3(3):514–540.
doi:10.3390/ph3030514Annane D, Renault A, Brun-Buisson C, et al. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. N Engl J Med. 2018;378(9):809–818.
doi:10.1056/NEJMoa1705716RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704.
doi:10.1056/NEJMoa2021436Czock D, Keller F, Rasche FM, Haussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61–98.
doi:10.2165/00003088-200544010-00003Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997;350(9074):309–318.
doi:10.1016/S0140-6736(97)01300-7Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317–328.
doi:10.1056/NEJMoa1613849Marik PE, Varon J. Requirement of perioperative stress doses of corticosteroids: a systematic review of the literature. Arch Surg. 2008;143(12):1222–1226.
doi:10.1001/archsurg.143.12.1222Venkatesh B, Finfer S, Cohen J, et al. Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med. 2018;378(9):797–808.
doi:10.1056/NEJMoa1705835